College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, People's Republic of China.
National Engineering Research Center for Modernization of Traditional Chinese Medicine - Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University, Ganzhou 342700, People's Republic of China.
Int J Nanomedicine. 2020 Apr 22;15:2717-2732. doi: 10.2147/IJN.S234240. eCollection 2020.
Phototherapy is a potential new candidate for glioblastoma (GBM) treatment. However inadequate phototherapy due to stability of the photosensitizer and low target specificity induces the proliferation of neovascular endothelial cells for angiogenesis and causes poor prognosis.
In this study, we constructed c(RGDfk)-modified glycolipid-like micelles (cRGD-CSOSA) encapsulating indocyanine green (ICG) for dual-targeting neovascular endothelial cells and tumor cells, and cRGD-CSOSA/ICG mediated dual effect of PDT/PTT with NIR irradiation.
In vitro, cRGD-CSOSA/ICG inhibited cell proliferation and blocked angiogenesis with NIR irradiation. In vivo, cRGD-CSOSA/ICG exhibited increased accumulation in neovascular endothelial cells and tumor cells. Compared with that of CSOSA, the accumulation of cRGD-CSOSA in tumor tissue was further improved after dual-targeted phototherapy pretreatment. With NIR irradiation, the tumor-inhibition rate of cRGD-CSOSA/ICG was 80.00%, significantly higher than that of ICG (9.08%) and CSOSA/ICG (42.42%). Histological evaluation showed that the tumor vessels were reduced and that the apoptosis of tumor cells increased in the cRGD-CSOSA/ICG group with NIR irradiation.
The cRGD-CSOSA/ICG nanoparticle-mediated dual-targeting phototherapy could enhance drug delivery to neovascular endothelial cells and tumor cells for anti-angiogenesis and improve the phototherapy effect of glioblastoma, providing a new strategy for glioblastoma treatment.
光疗是胶质母细胞瘤(GBM)治疗的一种潜在新候选方法。然而,由于光敏剂的稳定性和低靶特异性,光疗不足会诱导新血管内皮细胞增殖以促进血管生成,并导致预后不良。
在这项研究中,我们构建了 c(RGDfk)修饰的糖脂样胶束(cRGD-CSOSA),用于双靶向新血管内皮细胞和肿瘤细胞,并且 cRGD-CSOSA/ICG 在近红外(NIR)照射下介导 PDT/PTT 的双重效应。
体外,cRGD-CSOSA/ICG 在 NIR 照射下抑制细胞增殖并阻断血管生成。体内,cRGD-CSOSA/ICG 在新血管内皮细胞和肿瘤细胞中表现出增加的积累。与 CSOSA 相比,在双重靶向光疗预处理后,cRGD-CSOSA 在肿瘤组织中的积累进一步提高。用 NIR 照射,cRGD-CSOSA/ICG 的肿瘤抑制率为 80.00%,明显高于 ICG(9.08%)和 CSOSA/ICG(42.42%)。组织学评价显示,在 NIR 照射下,cRGD-CSOSA/ICG 组的肿瘤血管减少,肿瘤细胞凋亡增加。
cRGD-CSOSA/ICG 纳米颗粒介导的双重靶向光疗可以增强药物向新血管内皮细胞和肿瘤细胞的传递,以实现抗血管生成,并提高胶质母细胞瘤的光疗效果,为胶质母细胞瘤的治疗提供了一种新策略。